AIM ImmunoTech Inc. — FY2022 Form 10-K Summary
Business context and reporting period
For the fiscal year ended December 31, 2022. AIM is a clinical-stage immunopharmaceutical company focused primarily on Ampligen (rintatolimod), an investigational therapy being studied in cancer, ME/CFS and post-COVID conditions, with additional antiviral research. Ampligen is not FDA-approved or marketed in the United States; it has Argentine approval for severe CFS, but commercial launch there remained pending final product inspection and release testing. Alferon N Injection is FDA-approved for certain genital warts, but sales are halted because the company has no finished-goods inventory and production is on hold.
Financial results and liquidity
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue | $141,000 | $135,000 |
| Research and development expense | $6.99 million | $7.67 million |
| General and administrative expense | $13.07 million | $8.67 million |
| Operating loss | $19.92 million | $18.84 million |
| Net loss | $19.45 million | $19.13 million |
| Basic and diluted loss per share | $0.40 | $0.40 |
| Cash used in operating activities | $16.11 million | $13.97 million |
Revenue was limited to Ampligen clinical treatment and cost-recovery programs; the company reported no material operating revenue. Gross margin is not meaningful given the very small revenue base and absence of production costs in 2022. G&A increased $4.40 million, principally reflecting higher legal fees; R&D decreased $0.68 million. Net loss increased $0.32 million, with higher G&A and investment losses substantially offset by lower financing costs, impairment and R&D expense, among other items.
At December 31, 2022, cash and cash equivalents were $27.05 million and marketable securities were $7.14 million, or $34.19 million combined, down $14.08 million from year-end 2021. Total current assets were $36.32 million against current liabilities of $1.36 million. The balance sheet reports no debt; operating lease liabilities totaled $0.84 million, and Series B convertible preferred stock had a stated value of $696,000. Investing cash flow included $3.9 million of proceeds from the facility sale in the cash flow statement; the business discussion describes $3.7 million net proceeds. Financing cash flow was $80,000, versus $8.19 million in 2021, when equity issuance generated $13.04 million in net proceeds.
Material changes, outlook and risks
- Management estimated that year-end funds could support anticipated operating needs and current clinical trials for approximately 16 months. AIM warned it may need further financing; its effective shelf registration permits offers of up to $100 million, with possible dilution. The company does not expect material operating revenue in the near term.
- The Phase 2 AMP-270 pancreatic cancer trial received FDA clearance and IRB approval in 2022 and commenced; the company reported approximately $1.73 million of trial expense for the year. A Phase 2 post-COVID trial, AMP-518, cleared the FDA IND process in October 2022; an amended protocol received IRB approval in March 2023.
- The 2013 FDA Complete Response Letter for Ampligen’s ME/CFS application remains unresolved; additional clinical and nonclinical work and data analyses are needed. Argentine commercial sales also remained subject to regulatory release steps.
- Alferon production has no definitive restart timetable. The company sold its New Brunswick facility in November 2022 and leased a new New Jersey R&D facility; manufacturing scale-up, third-party manufacturing, raw-material availability and regulatory approval remain material dependencies.
- Management reported a $1.68 million loss on investments in 2022. The company also sold $20.5 million of New Jersey operating-loss carryforwards for approximately $1.68 million and recorded a deferred tax asset for losses expected to be sold in 2023.
- Key risks include continued losses and financing needs, clinical and regulatory uncertainty, manufacturing and supply constraints, competition, limited product-liability insurance, stock dilution and volatility, and litigation. The company disclosed an ongoing BioLife contract dispute and activist-related litigation; the Delaware Court of Chancery rejected the activist’s nomination challenge in October 2022, and the activist did not appeal.
- The company reported effective disclosure controls and internal control over financial reporting, with no material weaknesses identified by management. The auditor did not audit internal controls. The audited financial statements received an unqualified opinion; the auditor identified valuation of redeemable warrants as a critical audit matter.
Most important facts for investors to verify
- Cash burn and actual runway against management’s approximately 16-month estimate, including any subsequent financing or dilution.
- Enrollment, costs, safety and efficacy data for AMP-270, AMP-518 and other trials; distinguish preliminary or investigator-reported findings from controlled, confirmatory results.
- Timing and requirements for Argentine Ampligen launch, and whether Alferon manufacturing can resume with FDA approval.
- Cash and investment balances, investment-loss exposure, and the stated sale proceeds for the New Brunswick property.
- Current status and potential financial impact of the BioLife dispute and remaining activist-related legal proceedings.